The study identifies mutations in the thyA gene as a cause of para-aminosalicylic acid (PAS) resistance in Mycobacterium tuberculosis, with 37% of PAS-resistant isolates having such mutations.

The paper discusses the genetic adaptation of Staphylococcus aureus in cystic fibrosis patients, highlighting the role of horizontal gene transfer, mutations, and regulatory mechanisms in the development of persistent infections and resistance. It emphasizes the importance of whole genome sequencing in understanding the population dynamics and evolution of S. aureus in the CF airways.

The study identifies genes involved in resistance to anti-tubercular drugs through chemical-genetic interaction analysis, highlighting gyrA, rpoB, thyA, ino1, and kasB as key players in resistance mechanisms for fluoroquinolones, rifampin, sulfamethoxazole, and isoniazid.

The study identifies a G172C mutation in the thyA gene, leading to thymine auxotrophy and resistance to TMP-SMX in E. coli isolates from a patient with recurrent bloodstream infections.

The study identifies thyA, folC, and dfrA mutations as the primary mechanisms of para-aminosalicylic acid (PAS) resistance in Mycobacterium tuberculosis. It establishes 4 μg/ml as the critical concentration for distinguishing PAS-susceptible and resistant isolates.

The study identified multiple AMR genes and mutations in Mycobacterium tuberculosis variant bovis strains from Mato Grosso, Brazil, including resistance to pyrazinamide, isoniazid, rifampicin, streptomycin, ethambutol, ethionamide, fluoroquinolones, kanamycin, capreomycin, paraminosalicylic acid, cycloserine, bedaquiline, linezolid, and delamanid.

The study identifies multiple drug resistance markers in the clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001, including mutations in genes such as rpoB, katG, AAC(2')-Ib, gyrA, gyrB, embB, pncA, thyA, embC, embR, and iniA, which confer resistance to various antibiotics.

The study identified mutations in thyA, thyX, folC, and ribD genes, along with intergenic regions, that contribute to PAS resistance in M. tuberculosis. These mutations were validated through complementation assays and MIC testing.

The study reveals that E. coli develops resistance to antibiotics faster than to antimicrobial peptides (AMPs). Trimethoprim-resistant E. coli with mutations in the thyA gene shows increased susceptibility to pexiganan.